Related Experiment Video
Updated: May 18, 2026
Extracellular Vesicle Tissue Factor Activity Assay
Published on: December 29, 2023
Differential investigations from plasma-derived and recombinant Factor IX revealed major differences in
G Chevreux1, V Faid, M-H Andre
1LFB Biotechnologies, Courtaboeuf Cedex, France LFB Biomédicaments, Courtaboeuf Cedex, France. chevreuxg@lfb.fr
Abstract:
Post-translational modifications (PTMs) located on the activation peptide (AP) of recombinant FIX (rFIX, BeneFIX(®) ) and plasma-derived FIX (pdFIX, Betafact(®) ) have been investigated by mass spectrometry to review the structural differences between these two products. Three major structural differences were pointed out. rFIX contains a low amount of phosphorylated and sulphated AP (4% for rFIX vs. 70% for pdFIX); rFIX N-glycans are only sialylated in the α2-3 linkage, whereas pdFIX N-glycans contain both type of α2-3 and α2-6 linkages, and rFIX does not contain any sialyl Lewis(X) glycoantigens contrary to pdFIX. These variations might participate in the in vivo potential different behaviours of the two molecules.
